Menu Search
Equities

PTC Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BH3:FRA

PTC Therapeutics Inc

Actions
  • Price (EUR)60.00
  • Today's Change-1.50 / -2.44%
  • Shares traded67.00
  • 1 Year change+25.52%
  • Beta0.4992
Data delayed at least 15 minutes, as of Feb 06 2026 07:11 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

  • Revenue in USD (TTM)1.78bn
  • Net income in USD751.72m
  • Incorporated1998
  • Employees939.00
  • Location
    PTC Therapeutics Inc500 Warren Corporate Center DriveWARREN 07059United StatesUSA
  • Phone+1 (302) 636-5400
  • Fax+1 (302) 636-5454
  • Websitehttps://www.ptcbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.